field. These areas offer benefits for the development of new products and promote new properties of the materials used, which could be essential in the effectiveness of the final product. They work at the atomic, molecular, and supramolecular levels, and can manufacture new devices and systems with new properties and functions. In 1959, Richard P. Feynman, who worked on the Manhattan project at Los Alamos during World War II in his prescient talk 'There is plenty of room at the bottom', proposed to produce devices using small machine tools to make smaller devices, these to be used in turn to make still smaller devices and so on down to the atomic level.
Nanomedicine is a part of the research and development in the nanotechnology field. Carriers that can transport bioactive molecules are being made smaller, less toxic, and more effective by using tools from nanotechnology, and the scientific community is at the beginning of an avenue in new drug delivery systems.
The chemical, physical and, biological properties of the materials at the nanoscale level present unprecedented differences in comparison to the original material, because the quantum mechanic interactions at the atomic level are influenced by the fluctuation of the material on the nanoscopic scale.
Nanotechnology can offer solutions and benefits in many areas such as:
Imaging and diagnostics that can allow diagnosis of cancer at an easily cured, early stage [1] ; Systems that permit the evaluation in real time of the effectiveness of a treatment [1] ; Multifunctional targeting systems that can overcome the biological barriers and transport drugs at high local concentrations, within a desirable time, directly to the cancer cells and neighboring tissue, that play an important role in cancer development and metastasis [1] ; Substances able to detect molecular changes and to prevent the transformation of pro-cancer cells into cancer cells [1] ; Detection systems, which can recognize mutations that can lead to cancer, and genetic markers, which can detect a predisposition to cancer [1] ; Research tools that offer the opportunity to identify fast new targets for clinical research and to predict drug resistance [1] . [2] .
Nanotechnology and formulations of bioactive molecules:
Nanotechnology can provide benefits in the diagnosis and treatment of several diseases by increasing the specificity of drugs and the delivery of bioactive molecules to the target tissues [2] . The area of drug delivery through biocompatible and biodegradable nanoparticles has grown in the recent past. Over the past decades, there has been interest in designing and developing nanoparticles as controlled release systems. Biological nanostructures include lipid nanotubes, lipid nanospheres, lipid nanoparticles, lipid emulsions, circular peptides, chitosan, viral nanoparticles, and nucleic acid nanostructures [2] .
Drug carriers for bioactive natural products:
In the past decades, the modulation of drug delivery systems is of growing interest since the ability to deliver bioactive molecules can alter pharmakokinetic properties and tissue distribution. The major challenge in drug delivery is to control the distribution of bioactive molecules in various organs after systemic administration. The inefficient drug delivery to the target tissue and the side effects after administration is due to the lack of sufficient drug carriers that can influence the pharmacokinetics and the biodistribution of the administered molecules. A large number of drugs have not been effective due to their inability to reach the target tissue. It is obvious that the design and development of drug carriers is a difficult issue, and their physicochemical parameters should be under control in the biological media in order to achieve delivery systems that can provide essential breakthroughs in the fight against diseases. Natural compounds, especially those derived from plant sources, play a significant role as new therapeutic candidates in the drug discovery process. According to the experience of the past decades, the lipophilicity, during the development process of new drugs from natural sources, is considered as the main delivery problem, while the toxicity and the low bioavailability affect the final effectiveness. Although many lipophilic compounds have been reported in the literature to exhibit significant in vitro pharmacological activity, they may not have been further investigated in vivo because of difficulties in administration due to their limited water solubility. Several attempts have been made to overcome the poor water solubility of bioactive natural compounds, as well as to minimize any undesired effects on healthy issues. In such cases, several new carriers have been designed and introduced in the development process of a drug in order to overcome the water insolubility and to permit further in vivo investigation. The role of the carrier on the pharmacological activity of the active compound is of importance, since it drastically affects its pharmacokinetic properties, as well as its pharmaceutical effectiveness and toxicity. With the exception of the lipophilicity problem, it is well known that high toxicity should be taken into account. The Vinca alkaloids and camptothecin and its derivatives, among others, are considered to be highly toxic to healthy tissues, despite their proven effectiveness against cancer diseases.
A bioactive compound is usually administrated using either oral or injection routes dispersed into an inert carrier. Drug delivery systems are today of great importance and based on the materials used they can be categorized as follows:
Biological materials: lipids, peptides, polysaccharides Polymeric materials: poly(lactic acid), poly (glycolic acid), dendrimers Silicon based materials: silicon, silicon dioxide Carbon based materials: carbon Metallic materials: gold, silver, palladium, platinum.
All these materials can be used for producing either micro-or nano-structured forms for drug delivery.
Such structures, following the order of the above category of materials, are: liposomes, micelles, dendrimers, nanopores and nanoneedles, nanotubes, fullerenes, and nanoshells [3] . 
Lipid-based drug carriers:
One of the most promising groups of nanoparticles is liposomes ( Figure 1 ). These belong to the class of lipid based drug carriers; they possess the ability to encapsulate bioactive compounds. Over the last years, liposomes have been proved to be adequate drug carriers [4] . The physicochemical properties of liposomes, such as lipid composition, surface charge and size, can modulate their in vivo behavior, resulting in an improvement of their pharmacokinetic properties, as well as the pharmacological response to the encapsulated drugs [5, 6] , while on the other hand, they may reduce possible drug side effects. The structural units of liposomes are amphiphile molecules, mainly phospholipids. Bangham and coworkers observed that lipids dispersed in water formed self-closed lipid structures [7] . This first observation took place after egg yolk lecithin had been dispersed in water. According to Lasic and Papahadjopoulos, liposomes are self-assembling colloidal particles in which a lipid bilayer encapsulates a fraction of the surrounding medium [7] . Liposomes have found several applications in biology and medicine, as well as in several fields of science and technology. Liposomes, non-toxic, biocompatible and biodegradable vesicles, represent ideal formulations as drug delivery systems, while they can be used in, for example medical diagnosis, and cosmetics.
The medical applications of liposomes have included the development of several new drug formulations applicable to a broad range of therapeutics. For example, the encapsulation into a liposomal formulation has improved the efficiency and toxicity of several anticancer drugs [7] .
The practically unlimited liposomal formulations, which can be produced by using different lipid compositions, make liposomes a valuable nanodevise for drug targeting. [8, 9] .
The release kinetics of a drug is a crucial parameter for controlling its pharmacokinetic behaviour. A bioactive compound can be released with a near zeroorder kinetic profile, which is ideal from a pharmacokinetic point of view. Studies concerning an anti-inflammatory agent [10] compared its macroporous copolymer carrier and a microporous copolymer carrier containing nanochannels. The results concerning the release kinetics showed that the drug is released from the microporous copolymer carrier containing nanochannels in near zero-order fashion. Decrease in release rate of an anticancer molecule is ideal and a novel approach is the entrapment of liposomes in polymeric microspheres and the progressive release of the intact liposomes from the biodegradable matrix [11] . Other approaches are based on the encapsulation of liposomes in microcapsules in order to either modulate the release of the encapsulated drug [12] or to produce liposome-like microspheres [13] . A new approach for controlling the release of the anticancer molecule doxorubicin has been recently reported [14] . A novel liposomal formulation [modulatory liposomal controlled release system (MLCRS)] composed of hexadecylphosphocholine (HePC), an antitumor ether lipid, egg-phosphatidylcholine and sterylamine (HePC: EPC: SA) 10:10:0.1 (molar ratio) and a doxorubicin-polyamidoamine (PAMAM) dendrimer complex was attached to liposomes and compared to that of a conventional liposomal system with the same composition encapsulating doxorubicin by the pH gradient method. The main advantage of the new liposomal formulation is the controlled and sustained [modulated] release of the encapsulated doxorubicin; its release is controlled by the complexation of doxorubicin in the dendrimer's internal cavity. However, the MLCRS system was found advantageous to that of the conventional liposomal formulation, reducing the percentage rate of doxorubicin's release at 37 o C in 50% RPMI culture medium for the 48 h incubation period [14] .
Dendrimers (Figure 2 ) are synthetic, hyperbranched, three dimensional macromolecules (polymers}, having a diameter of 1 to 100 nanometers (nanoparticles) and a series of bonds that emanates from the centre of the core; contrary to traditional "linear" polymers, they possess fractal architecture, nanoscaled size, and unique physicochemical properties. Their name derives from the Greek word dendro (tree) and meros (part), because the groups that evolve out from the centre possess repeatability. They are small in size, and exhibit a low polydispersity that can contribute to a reproducible pharmacokinetic behaviour. The main characteristics of dendrimers are their multiple reactive groups, a well-defined structure and their ability to encapsulate drugs in their internal spaces [15, 16] . An ideal dendrimer as a drug delivery system must be nontoxic, non-immunogenic, and biodegradable [16] . The synthesis of dendrimers is based on repeated reaction steps, where every completed series creates a new generation. The poly(amidoamine) (PAMAM) dendrimers are the first complete dendrimer family that has been synthesized, characterized and commercialized. They are considered safe and non-, immunogenic, and they are used in drug delivery, delivery of antisense nucleotides and gene therapy both in vitro and in vivo [17] . Dendrimers and dendrons have already been proposed for drug complexation and transport; especially lipid dendrons that can either produce higher order lamellar structures called "dendrisomes" [18] or aggregate to form nanosystems [19] . Compared to traditional linear polymers, dendrimers have a more precisely controlled chemical structure, an almost globular shape, a single molecular weight, and not a distribution of molecular weights (as linear polymers do), and are composed of three distinct areas: a. the core from which they branch out, b. the branching units that form the dendrimer, and c. an external surface with many functional groups (Figure 2) .
The core and the repeating units determine the microenvironment in the internal space of the molecule and the external functional groups determine the solubility and the physical and chemical interactions with its immediate surroundings. Therefore, the combinations of these three areas determine the physical and chemical properties of the molecule [15, 16] .
Starting from the mid-80s, after the pioneering work of Tomalia et al. [20] and Newkome et al. [21] , research in this field has attracted a vivid interest and has focused on the design and synthesis of dendrimers with specific physical and chemical properties. The aim was to provide applications of significant scientific and commercial value in fields such as biomedicine.
In biomedicine they are used for diagnostic and therapeutic purposes. In diagnosis, dendrimer-Gd III complex is used in magnetic resonance imaging (MRI agents) [22] As DNA biosensors [1] In therapeutics, • In gene therapy (gene transfection) [1] • In 10 B cancer treatment (boron neutron capture therapy) [23] • As antibiotic carriers and antiviral drugs. [2, 8] The advantage of dendrimer use as drug delivery agents is based on their ability to control the chemical structure that results from a controlled synthesis procedure. This offers the possibility to produce molecules with special properties, such as watersoluble groups in the outer layer and internal hydrophobic cavities that permit the encapsulation of other molecules, such as medicines, into the dendrimer. The advantage of dendrimers over micelles is that they can form unimonolayer micelles, where the hydrophobic and lipophilic parts are covalently linked together [24] . Therefore, their structure is static rather than dynamic and it can be maintained intact in a variety of concentrations and solvents. A dendrimer family that has been extensively investigated as drug carriers is PAMAM. Hydrophilic members of this family possessing either hydroxy-or ester-groups have been studied regarding their capacity to encapsulate small acidic molecules. Spectroscopic techniques have shown that stable ionic bonds are formed in the interior of the dendrimers. Other measurements (for example, flow calorimetry) have demonstrated that dendrimers can release these molecules on contact with the biological milieu. Another class of dendrimers that has been developed and studied is the polyesteric dendrimers [25] . These usually possess asymmetry, and are characterized by their ability to encapsulate large medicinal molecules, such as doxorubicin [26] .
The specific characteristics of dendrimers have contributed to an exponential increase of their applications in biomedicine as diagnostics, therapeutic agents, and drug delivery systems. Today they are used by US industries for drug formulation and they are characterized as smart devices. An investigational new drug application form (IND) has been filed to FDA in order to begin Phase I clinical trials for an antibiotic drug based on dendrimer technology [1] .
Dendrimers as drug carrier systems offer advantages such as:
Prolongation of the drug's circulation time Protection of the drug from its surroundings Increase its stability, possibly its effectiveness, and its ability to target the diseased tissue.
These very important properties of dendrimers and the multitude of their uses in medicine have caused an intense interest from the scientific community and pharmaceutical industry. It is not by chance that in countries such as the USA, Australia, and the UK, where a long tradition of cooperation among universities and research institutes exists on one hand, and industry on the other, very soon after the appearance of dendrimers in the literature, companies were founded for the commercial use of the research results. For example, the NanoBio Corporation is a biopharmaceutical company, founded in 2000, aiming at developing and commercializing nanotechnology that has been developed by the founder of the field, Professor D. Tomalia at the University of Michigan.
It is worth mentioning that, in general, the field of developing systems for transport and selective targeting of bioactive compounds is more and more attracting the interest of companies involved in the health sector, resulting in a very competitive situation. For instance, in the USA, Alza, which deals with developing systems for the transport of drugs, was bought in 2001 by Johnson & Johnson for $ 10.5 billion (US). In the March 1 st , 2004 issue of Chemical & Engineering News there is an extensive review dedicated to the industry that develops and produces such systems [27] .
Dendrimers as carriers for bioactive natural compounds:
The ability of natural compounds from plants, animals and microbes for the effective treatment of maladies is well established. A great number of these compounds serve as lead compounds for semi-synthetic preparations in order to produce more effective drugs. Approximately 500 plants are therapeutically used as raw materials for the production of final medicinal products. In Europe, there is a strong market of phytomedicines, probably due to the changes in life style of the European population and the increasing lifespan. However, the number of patients with chronic diseases is increasing and therapies need improvement in terms of effectiveness and safety. The World Health Organisation (WHO) estimates that worldwide, herbalism is three or four times more commonly practised than allopathic medicine. It has been estimated that up to 50% of the prescribed drugs in the USA contain one or more natural compounds [3] . In the middle of the 20 th century the trend was either to ignore or even remove botanical drugs and natural molecules from the official compendia due to the production of chemically synthesized new molecules. New semi-synthetic and natural products have been introduced into therapy such as irinotecan, topotecan, paclitaxel, tacrolimus (FK-506), capsaicin, dronabinol (synthetic form of Δ 9 -tetrahydrocannabinol), galanthamine, and acarbose, which are new weapons against cancer and infections. One of the main problems to formulate natural products for iv and ip administration, is their poor water solubility. There are six water-miscible co-solvents approved by the US Food and Drug Administration; glycerin, poly(propylene glycol), poly(ethylene glycol) (PEG), N,N-dimethylformamide, cremophor, and ethanol [3] , which are more or less toxic and therefore their use is limited.
The questions that arise according to the above are: How can we improve the effectiveness of the extremely important natural bioactive compounds by controlling their pharmacokinetic parameters, their bioavailability, and their targetability to the specific tissues? How can we reduce the undesired side effects and toxicity of natural compounds? How can we improve their water solubility? New and innovative drug delivery systems, such as dendrimers among others, offer new and attractive properties and solve more or less these problems. However, chemical molecules or biologicals, such as natural compounds or proteins that were rejected for administration because of either their toxicities or because of their low water solubility, can be introduced again in therapeutics by offering new improved properties due to the delivery system in which they could be incorporated [2] .
Cancer is known to be one of the main causes of death in the developed world, despite the successes in the understanding of the mechanisms of carcinogenesis and the new methods for diagnosis and therapeutic treatment. Nanotechnology, through the use of systems for administration and transport of anticancer agents [28] , (systems of this kind include liposomes and dendrimers), participates in the struggle against cancer. In the USA, 1500 people die per day from cancer, while cancer chemotherapeutic drugs based on plant secondary metabolites are 11 in number, based on different structural classes i.e bisindole alkaloids, camptothecin derivatives, podophyllotoxins, and taxanes. Anticancer molecules incorporated either within a dendrimer structure or complexed covalently with their final groups could facilitate their delivery to tumors, reducing systemic side effects. New bioactive proteins, recombinant DNA, and vaccines which are the research target of Biotechnology Companies, require novel delivery systems, such as dendrimers, which could be able to minimize side effects and lead to better patient tolerance. Recently, a review article concerning dendrimer-drug interactions was published [29] dealing with the categories of types of complexation of dendrimer-drug, resulting in better drug solubility and bioavailability. Dendrimers of low generation (i.e. up to G2) have a different shape than those of higher generations. This phenomenon seems to affect dendrimer-drug complexation depending on the nature of interaction. The dendrimer-drug interactions are divided as follows:
Drug entrapment within the dendrimers' branches could be electrostatic, hydrophobic and hydrogen bonded, depending on the nature of the drug's chemistry [29] .
Interactions of the drug with the surface chemical groups of the dendrimer could be electrostatic and covalent [29] .
Drug encapsulation within dendrimer branches can offer desirable controlled release properties of the drug, especially in the case of anticancer drugs. The zero-order kinetic profile, which is ideal from the pharmacokinetic point of view, can be achieved by controlling the size of the particle carrier used to deliver the bioactive compound. Dendrimers are characterized as real nanoparticles due to their nano size, which is 5.5 nm diameter in the case of PAMAM G4 and to the ideal size polydispersity, and for this reason they are referred to as attractive drug carriers. It is of interest to note that, to the best of our knowledge, the only bioactive natural compound isolated from a plant that has been incorporated into dendrimers is paclitaxel [3] . According to Ooya et al. [3] , polyglycerol dendrimers (PGDs) were synthesized, characterized and used for incorporating paclitaxel, a poorly soluble in water, bioactive molecule. The results showed that paclitaxel's solubility was much higher than that in PEG400. The complexation of dendrimer-paclitaxel seems to increase its solubility while the release rate of the drug from the complex depends on the dendrimer shape and generation. The encapsulation of bioactive natural compounds into commercially available dendrimers (i.e. PAMAM), as well as the nature of drug-dendrimer interactions, and the physicochemical properties of the complexes, are the main research interests of our laboratory.
Today, several laboratories worldwide work on the complexation of bioactive natural compounds, especially those derived from the plant kingdom [30] , in order to improve the therapeutic properties of the compounds, to reduce their toxicity, and to solve the problem of their low solubility.
In conclusion, nanotechnology is a challenge for producing effective carriers for natural compounds by offering advantages over other conventional carrier systems. Dendrimers, which could be characterized as real nanodevices, exhibit such properties, which can allow the development of new and efficient drug delivery systems, and in this way they can improve the pharmacological efficacy of many novel and old natural compounds.
